Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery

Completed · Phase 1

Conditions studied: Tumors, Breast

In brief

Surgery is the primary treatment modality for many types of cancer and the extent of surgical resection is directly related to patient survival. However, it is often difficult for surgeons to distinguish normal from neoplastic tissue or to detect metastatic disease or tumor-infiltrated lymph nodes. In some sites, surgical precision is also required to avoid damage to critical normal tissues. The purpose of this exploratory study is to evaluate the intra-operative and ex vivo fluorescence of BLZ-100 in tumor samples from subjects with breast cancer.

Key facts

Study ID

NCT02496065

Run by

Blaze Bioscience Inc.

People needed

30

Starts

2015-07-01

Expected to finish

2017-01-01

Last updated by the study team

2017-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female subject aged 18 years or older.
• Diagnosed solid tumor scheduled for surgical excision. Subjects with recurrent disease will be eligible only if the duration between last tumor surgery and scheduled new surgery is ≥3 months.
• Able to provide written informed consent.
• If of child-bearing potential, agree to continued use of two reliable methods of contraceptive from study entry (time of informed consent) through 30 days after BLZ-100 administration. Male subjects with vasectomy do not need to use a second form of contraceptive.
• Available for all study visits and able to comply with all study requirements.

You may not qualify if…

• Suspected central nervous system (CNS) tumor(s) or sarcoma.
• Female who is lactating/breastfeeding.
• Female with a positive pregnancy test or who is planning to become pregnant during the duration of the study.
• Karnofsky Performance Status of <60%.
• Any of the following laboratory abnormalities at Screening:
• Neutrophil count <1.5 x 109/L
• Platelets <75 x 109/L
• Hemoglobin <10 g/dL (may be determined following transfusion)
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN)
• Total bilirubin >1.5 x ULN (unless Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction)
• International Normalized Ratio (INR) >1.5 x ULN
• Creatinine >1.5 x ULN
• QTc prolongation >480 msec.
• History of hypersensitivity or allergic reactions requiring corticosteroids, epinephrine, and/or hospitalization.
• Uncontrolled asthma or asthma requiring oral corticosteroids.
• Known or suspected sensitivity to diagnostic imaging contrast agents.
• Known or suspected sensitivity to indocyanine green (ICG).
• Unstable angina, myocardial infarction, known or suspected transient ischemic events, or stroke within 24 weeks of start of Screening.
• Uncontrolled hypertension.
• Initiation of new photosensitizing drugs within 30 days of Screening.
• Use of any ongoing medications which might generate fluorescence or, according to the medication label, might generate a photochemical reaction. These include haematoporphyrin derivatives and purified fractions, Photofrin®, and the precursors of protoporphyrin IX (5-Aminolevulinic acid) used in Gliolan or Hexvix.
• Receipt of an investigational drug or device within 30 days of enrollment.
• Prior treatment with BLZ-100.
• Any concurrent condition, including psychological and social situations, which, in the opinion of the investigator, would adversely impact the subject or the interpretation of the study data.

Where it is running

• Overlake Medical Center — Bellevue, Washington, United States
• University of Washington Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.